Nachrichten zur Eli Lilly & Co Aktie

Obesity market sales potential tightens as Novo and Lilly enter new era

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade…

Cramer’s week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data

AMD, Alphabet and Amazon are among the heavyweight companies reporting earnings in the week ahead.…

Why the Market Dipped But Eli Lilly (LLY) Gained Today

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.27% move from the…

Futures: Risk-Off Shift For Market?

Google, AMD, Eli Lilly, Amazon and Palantir headline another big earnings week.…

Eli Lilly CEO says Medicare coverage of obesity drugs could change the game for upcoming pill launch

Lilly CEO Dave Ricks is confident in the ability of the companys pill to compete and is preparing for a…

Eli Lilly looks to sharpen its domestic supply edge by building another U.S. plant

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections

The plant will help make Lillys experimental drug called retatrutide, which has shown the highest weight loss seen to date…

Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push

Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in…

FDA Decision on Eli Lillys Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock?

The target action date for orforglipron is now April 10.…

Should You Buy Eli Lilly Before Feb. 4?

Is there another beat-and-raise in the pharmaceutical giants near future?…

Trump says Eli Lilly to build six US plants

U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and…

Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless

U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on…

Eli Lilly partners with Seamless Therapeutics on gene editing treatments for hearing loss

Eli Lilly and Co (NYSE:LLY) announced that it has entered a strategic global research collaboration and licensing agreement with Seamless…

Exclusive: Novos Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows

Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine…

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks By Reuters

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks…

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical…

Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks By Investing.com

Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks…

Where Will Eli Lilly Be in 10 Years?

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage wont last forever.…

Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog

…

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -2.12% move from the prior day.…

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Eli Lillys valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.…

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in…

Abivax CEO dismisses noise around rumored Eli Lilly bid

Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may…

Zacks Market Edge Highlights: TSLA, NVDA and LLY

Is the Magnificent 7 finished? NVDA shines while Tesla struggles and Eli Lilly surges, as Zacks Market Edge debates who…

Which Pharma Stock Stands Taller Right Now: LLY or PFE?

Eli Lillys Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment…

Prediction: 2026 Will Be the Year of Eli Lilly

A catalyst lies just ahead.…

Novo Nordisk shares rise 8% after Wegovy obesity pill has solid launch

The early data is a boost to the Danish drugmakers hopes of winning back more market share from Eli Lilly…

Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?

The choice isnt that hard.…

LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling

Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to…

Novos Wegovy pill tracks 3,071 prescriptions in first days of launch

Novo Nordisks Wegovy pill hit 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by…

Stocks making the biggest moves midday: Morgan Stanley, Coinbase, Taiwan Semi, Eli Lilly & more

Here are some of the names making big moves in midday trading.…

How Will Mounjaro and Zepbound Sales Aid LLYs Upcoming Q4 Results?

Eli Lillys Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset…

Eli Lillys Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief

Retatrutide is an exciting GLP-1 drug that has explosive potential.…

Why Eli Lilly Stock Gained 39.2% In 2025

The company is benefiting mightily from its portfolio of weight-loss drugs.…

Is It Time to Dump Your Shares of Eli Lilly?

What happens with Eli Lillys GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?…

The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Lam Research and Ampco-Pittsburgh

Microsoft headlines Zacks Analyst Blog as strong cloud, AI, and semiconductor trends shape outlooks across tech and healthcare.…

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?

Both companies now aim to win in the oral weight loss drug market.…

Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?

The gap may be too hard to close in the next 12 months.…

Eli Lilly (LLY) Laps the Stock Market: Heres Why

Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.64% move from its prior days close.…

Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab

Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San…

Heres Why Eli Lilly (LLY) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Abivax shares soar 23% as media report reignites M&A chatter

Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly…

RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models

Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug…

2026 is the year of obesity pills. Heres how they could reshape the GLP-1 market

Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly…

Eli Lilly-Backed Aktis Jumps 50% After $318 Million US IPO

Aktis Oncology Inc. shares jumped 50% in their trading debut after the clinical-stage biotechnology company raised $317.7 million in an…

Bull of the Day: Eli Lilly (LLY)

Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is…

Aktis Oncology upsizes IPO by 50%, attracts $100 million from Eli Lilly By Investing.com

Aktis Oncology upsizes IPO by 50%, attracts $100 million from Eli Lilly…

Warning: This Skyrocketing Stock Has a Hidden Risk

Novo Nordisks new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the…

Eli Lillys 2026 Resolution: Volume Is The New Price

…

Ventyx Biosciences stock surges after Eli Lilly acquisition talks By Investing.com

Ventyx Biosciences stock surges after Eli Lilly acquisition talks…